Should I buy Amphstar Pharmaceuticals, Inc. (AMPH) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Amphstar Pharmaceuticals, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Jefferies | 67 % | +28.8 % | 6 | $22 -16% |
| Piper Sandler | 67 % | +10.4 % | 6 | $20 -23% |
✅ Reasons to believe
- Few solid positives from analysts right now: of 6 ratings, only 0 buys, and the median price target ($20) is -23% below the price ($26). Caution prevails.
⚠️ Reasons to hesitate
- Even the most reliable firm on AMPH, Jefferies (67% hit rate, 6 scored calls), only targets $22 (call made on April 21, 2026, maturing on April 21, 2027) (-16%) in its most recent call. The stock may already have run past its target.
- The consensus is not unanimous: of 6 ratings, 5 are neutral and 1 is a sell.
- Limited upside: the median target is only -23% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on AMPH
Median target $20 (-23%) · 6 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Amphstar Pharmaceuticals, Inc. now?
We won't decide for you. The facts: 0% of analysts rate it a buy, median target $20 (-23%), and Jefferies (most reliable on AMPH, 67%) targets $22. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Amphstar Pharmaceuticals, Inc.?
The stated upside is small: the median target ($20) sits just -23% from the price ($26) (most reliable on AMPH: Jefferies, 67%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Amphstar Pharmaceuticals, Inc. still worth investing in?
It depends on the gap between the price ($26) and its estimated value: analysts target $20 on median (-23%), with 0% buys (most reliable on AMPH: Jefferies, 67%). Cross-check with their real reliability on AMPH and the cautions above. Information, not advice.
What's the main risk in buying AMPH?
Even the most reliable firm on AMPH, Jefferies (67% hit rate, 6 scored calls), only targets $22 (call made on April 21, 2026, maturing on April 21, 2027) (-16%) in its most recent call. The stock may already have run past its target.
→ Go deeper: the full Amphstar Pharmaceuticals, Inc. profile (consensus, analyst reliability, price target, performance).